There have been some significant cannabis deals done today in the hallowed halls of the Australian Stock Exchange.
The two deals are set to increase access for patients looking for medicinal cannabis and improve the quality of medicines being created in Australia.
First, Althea (ASX: AGH) has signed a supply and distribution agreement with Cannvalate to assist in the distribution of Althea’s products.
Cannvalate has one of Australia’s largest networks of medicinal cannabis prescribing clinics and has a national footprint.
The agreement will see Cannvalate distribute Althea’s products in Australia thus increasing access for those that require medicinal cannabis.
CEO of Cannvalate Dr. Sud Agarwal says his company is best suited as a distributor considering its expertise in educating clinicians and pharmacists about the benefits of specific medicinal cannabis products.
“Our specialist medical panel has reviewed Althea’s product range and have provided a detailed plan on how to target each of its products to the most appropriate specialists and our education team have been briefed to provide the support necessary to allow Althea to carve a strong market presence,” says Dr. Agarwal.
“We look forward to working with Althea and its team to ensure maximal uptake of its products in the Australian cannabis marketplace.”
Please read the full article here.